Quest Diagnostics to Add Roche's Elecsys to Alzheimer's Biomarker Test Portfolio

08:24 AM EDT, 08/24/2026 (MT Newswires) -- Quest Diagnostics (DGX) said Monday it is adding Roche's Elecsys Phospho-Tau Plasma blood test to its AD-Detect portfolio of biomarker tests to detect Alzheimer's disease. The company said it plans to offer a laboratory test service based on Elecsys in Q4 and incorporate the Roche test into future AD-Detect panels in 2027. Quest said the US Food and Drug Administration has cleared Roche's Elecsys blood test to assess amyloid pathology associated with Alzheimer's disease across primary and specialty care settings. Quest also said it will launch its newest AD-Detect lab-developed blood test with low 10% indeterminate rate so more patients can receive an actionable insight.